Vision of the ESMO

13890_PR < 5000 patients denied access to new, life-saving drugs every year in Europe

ESMO 2016: Scientific Programme Highlights

Anti-cancer medicines

Full-dose neoadjuvant chemotherapy: Interi

EORTC 18071

First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)

Primary analyss from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC.

ASCEND-5 study

AFFINITY phase 3 trial. Chemotherapy of Prostate Cancer

Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)

Results from ALLIANCE A031203 trial

Eribulin in Soft Tissue Sarcomas (Leiomyosarcoma)

ESMO 2016: Congress Highlights

13890_PR < 5000 patients denied access to new, life-saving drugs every year in Europe

MONALEESA-2 study and Novelties in breast cancer therapy

Full-dose neoadjuvant chemotherapy

EORTC 18071

Vision of the ESMO

New results in immun check point inhibition Lung Cancer

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients: An international multicentre hospital-based retrospective cohort study

Highlights of Late Breaking Trials

Checkpoint inhibitors for the treatment of orphan malignancies

New therapeutical option: A mechanism of action study. An oncolytic adenovirus in patients with colon, lung, bladder and renal carcinoma.

Highlights of Late Breaking Trials